References
- 1. Bravi L, Dejana E, Lampugnani MG. VE-cadherin at a glance. Cell Tissue Res. 2014;355(3):515-22.
- 2. Orsenigo F, Giampietro C, Ferrari A et al. Phosphorylation of VEcadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat Commun. 2012;3:1208.
- 3. Cicardi M, Aberer W, Banerji A et al. Classification, diagnosis, and approach to treatment for angiooedema: consensus report from the Hereditary Angiooedema International Working Group. Allergy. 2014;69(5):602-16.
- 4. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angiooedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213-7.
- 5. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angiooedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286-9.
- 6. Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angiooedema type III. Am J Hum Genet. 2006;79(6):1098-104.
- 7. Bork K, Kleist R, Hardt J, Witzke G. Kallikrein-kinin system and fibrinolysis in hereditary angiooedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis. 2009;20(5):325-32.
- 8. Mansi M, Zanichelli A, Coerezza A et al. Presentation, diagnosis and treatment of angiooedema without wheals: retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015;277(5):585-93.
- 9. Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic nonhistaminergic angiooedema. Am J Med. 1999;106(6):650-4.
- 10. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykininreceptor antagonist, in hereditary angiooedema. N Engl J Med. 2010;363(6):532-41.
- 11. Kaplan AP. Angiooedema. World Allergy Organ J. 2008;1(6):103-13.
- 12. Zuberbier T. A Summary of the New International EAACI/ GA2LEN/EDF/WAO Guidelines in Urticaria. World Allergy Organ J. 2012;5 Suppl 1:S1-5.
- 13. Zingale LC, Beltrami L, Zanichelli A et al. Angiooedema without urticaria: a large clinical survey. CMAJ. 2006;175(9):1065-70.
- 14. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angiooedema. N Engl J Med. 2002;347(8):621-2.
- 15. Bygum AM, Aygoren-Pursun EM, Caballero TMP et al. The hereditary angiooedema burden of illness study in Europe (HAEBOIS- Europe): background and methodology. BMC Dermatol. 2012;12:4.
- 16. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and longterm management of hereditary angiooedema. Ann Allergy Asthma Immunol. 2010;104(4):314-20.
- 17. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angiooedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407-14.
- 18. Lin RY, Shah SN. Increasing hospitalizations due to angiooedema in the United States. Ann Allergy Asthma Immunol. 2008;101(2):185-92.
- 19. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angiooedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy. 2011;66(2):192-6.
- 20. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angiooedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692-7.
- 21. Marcos C, Lopez Lera A, Varela S, Linares T, Alvarez-Eire MG, Lopez-Trascasa M. Clinical, biochemical, and genetic characterization of type III hereditary angiooedema in 13 Northwest Spanish families. Ann Allergy Asthma Immunol. 2012;109(3):195-200.
- 22. Vitrat-Hincky V, Gompel A, Dumestre-Perard C et al. Type III hereditary angio-ooedema: clinical and biological features in a French cohort. Allergy. 2010;65(10):1331-6.
- 23. Bork K. Hereditary angiooedema with normal C1 inhibitor. Immunol Allergy Clin North Am. 2013;33(4):457-70.